Lupus patients enrolled in major Long-Term observation study

NCT ID NCT06551389

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 300 adults with systemic lupus erythematosus (SLE) who are seen by a team of specialists at a hospital in Brest, France. Researchers will collect data on disease patterns, symptoms, and test results over time. The goal is to better understand lupus and improve how it is diagnosed and managed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could help doctors better understand lupus patterns and improve how they diagnose and manage the disease.

What could go wrong

This is an observational study, not a treatment trial, so it won't directly lead to new therapies. Results may take years and might not apply to all lupus patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arthritic joint disease arthropathy autoimmune disease immune system disorder musculoskeletal system disorder rheumatic disorder systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHRU de Brest

    RECRUITING

    Brest, 29609, France

    Contact Email: •••••@•••••